NCT07678138 — Huanhu Hospital Affiliated to Tianjin… neoantigen vaccine trial
Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma
Registry record
| Registry ID | NCT07678138 ↗ |
|---|---|
| Lead sponsor | Huanhu Hospital Affiliated to Tianjin Medical University |
| Collaborators | — |
| Phase | Phase NA |
| Status | Not Yet Recruiting |
| Indication | Glioblastoma |
| Enrollment | 9 participants (target) |
| Start date | 2026-06-30 |
| Primary completion | 2027-11-30 (est.) |
| Last registry update | 1 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07678138), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07678138?
NCT07678138 (Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma) is registered on ClinicalTrials.gov as Phase NA, sponsored by Huanhu Hospital Affiliated to Tianjin Medical University.
Is NCT07678138 recruiting?
As of the 2026-07-01 registry update, NCT07678138 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07678138?
The lead sponsor is Huanhu Hospital Affiliated to Tianjin Medical University.
What condition does NCT07678138 study?
The registered condition is Glioblastoma. Primary completion is listed as 2027-11-30 (estimated).
Are results available for NCT07678138?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07678138.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.